MedTrace Logo

Retrograde Delivery of BMAC (Bone Marrow Aspirate Concentrate) for Congestive Heart Failure

NCT01299324 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2014-08-19

No results posted yet for this study

Summary

The primary objective of this feasibility study is to provide clinical data to demonstrate the safety and activity of a concentrate of nucleated cells from bone marrow aspirate (BMAC) produced with the Harvest Bone Marrow Aspirate Concentrate System for treating patients diagnosed with congestive heart failure (CHF).

Conditions

  • Congestive Heart Failure

Interventions

DEVICE

BMAC infusion

Infusion of 60 mL of Bone Marrow Aspirate Concentrate

Sponsors & Collaborators

  • Harvest Technologies

    lead INDUSTRY

Principal Investigators

  • Amit Patel, MD · University of Utah

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-02-28
Primary Completion
2013-08-31
Completion
2013-10-31

Countries

  • Germany
  • India
  • Peru

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01299324 on ClinicalTrials.gov